Ultrasound Elastography Devices in 2025: Transforming Diagnostic Imaging with Precision and Speed. Explore Market Growth, Technological Advances, and the Future of Non-Invasive Tissue Assessment.

Executive Summary: Key Trends and Market Drivers in 2025
Market Size and Forecast (2025–2030): Growth Projections and CAGR Analysis
Technological Innovations: Shear Wave, Strain, and Beyond
Competitive Landscape: Leading Manufacturers and New Entrants
Clinical Applications: Oncology, Hepatology, and Musculoskeletal Uses
Regulatory Landscape and Standards (FDA, CE, and Global Bodies)
Regional Analysis: North America, Europe, Asia-Pacific, and Emerging Markets
Challenges and Barriers: Reimbursement, Training, and Adoption
Future Outlook: AI Integration, Portability, and Next-Gen Devices
Company Spotlights: Canon Medical, Siemens Healthineers, GE Healthcare, and Mindray (sources: global.medical.canon, siemens-healthineers.com, gehealthcare.com, mindray.com)
Sources & References

Executive Summary: Key Trends and Market Drivers in 2025

The ultrasound elastography devices market in 2025 is characterized by rapid technological advancements, expanding clinical applications, and increasing global adoption. Elastography, which enables non-invasive assessment of tissue stiffness, is becoming a standard adjunct to conventional ultrasound, particularly in liver disease, oncology, and musculoskeletal diagnostics. The integration of elastography into mainstream ultrasound systems is being driven by both established imaging leaders and innovative entrants, responding to rising demand for early, accurate, and cost-effective diagnostic tools.

A key trend in 2025 is the widespread adoption of shear wave and strain elastography modalities. Major manufacturers such as GE HealthCare, Philips, Siemens Healthineers, and Canon Medical Systems have integrated advanced elastography features into their flagship ultrasound platforms. These systems offer real-time quantitative measurements, improved image quality, and user-friendly interfaces, making elastography accessible to a broader range of healthcare providers. For example, Samsung Medison and Mindray are also expanding their elastography-enabled product lines, targeting both developed and emerging markets.

Regulatory approvals and updated clinical guidelines are further accelerating market growth. In 2025, elastography is increasingly recommended for routine liver fibrosis assessment, breast lesion characterization, and thyroid nodule evaluation. The World Health Organization and national health agencies are promoting non-invasive diagnostics to reduce the need for biopsies, especially in chronic liver disease management. This policy shift is expected to drive higher adoption rates in hospitals, imaging centers, and point-of-care settings.

Another significant driver is the miniaturization and portability of elastography devices. Handheld and cart-based systems are gaining traction, enabling use in outpatient clinics and remote settings. Companies like Fujifilm Healthcare and Hologic are investing in compact, high-performance solutions to meet the needs of decentralized healthcare delivery.

Looking ahead, the market outlook for ultrasound elastography devices remains robust. Ongoing R&D in artificial intelligence and machine learning is expected to enhance image interpretation and workflow efficiency. Strategic collaborations between device manufacturers and healthcare providers are likely to accelerate innovation and expand clinical evidence. As reimbursement policies evolve and awareness grows, the global ultrasound elastography market is poised for sustained double-digit growth through the next several years.

Market Size and Forecast (2025–2030): Growth Projections and CAGR Analysis

The global market for ultrasound elastography devices is poised for robust growth from 2025 through 2030, driven by increasing clinical adoption, technological advancements, and expanding applications in both diagnostic and interventional medicine. As of 2025, the market is characterized by a strong presence of leading medical imaging companies, ongoing product innovation, and a growing emphasis on non-invasive diagnostic tools for liver, breast, thyroid, and musculoskeletal diseases.

Key industry players such as GE HealthCare, Siemens Healthineers, Philips, Canon Medical Systems, and Samsung Medison continue to invest in research and development, introducing new elastography platforms and software upgrades that enhance image quality, quantification accuracy, and workflow efficiency. These companies are also expanding their product portfolios to address a broader range of clinical indications, including oncology, hepatology, and rheumatology.

The market outlook for 2025–2030 is underpinned by several factors:

Rising Prevalence of Chronic Diseases: The global burden of liver fibrosis, cancer, and metabolic disorders is increasing, fueling demand for non-invasive diagnostic modalities such as ultrasound elastography.
Technological Advancements: Innovations such as shear wave elastography, point shear wave, and strain elastography are being integrated into new ultrasound systems, improving diagnostic confidence and expanding clinical utility.
Regulatory Approvals and Guidelines: Regulatory bodies in North America, Europe, and Asia-Pacific are increasingly recognizing elastography as a standard of care for certain indications, supporting market expansion.
Healthcare Infrastructure Investments: Emerging markets are investing in advanced imaging technologies, further accelerating adoption rates.

Based on current trends and company statements, the ultrasound elastography devices market is expected to achieve a compound annual growth rate (CAGR) in the high single digits to low double digits between 2025 and 2030. The market size is projected to surpass several billion USD by the end of the forecast period, with Asia-Pacific and North America representing the fastest-growing regions due to large patient populations and increasing healthcare expenditures.

Major manufacturers such as GE HealthCare and Siemens Healthineers have publicly highlighted their commitment to expanding elastography capabilities, with ongoing product launches and clinical collaborations expected to further drive market growth. As the technology matures and becomes more widely accessible, ultrasound elastography is anticipated to become an integral component of routine diagnostic imaging worldwide.

Technological Innovations: Shear Wave, Strain, and Beyond

Ultrasound elastography devices have undergone significant technological advancements, particularly in the domains of shear wave and strain elastography. As of 2025, these innovations are reshaping clinical diagnostics by enabling more precise, non-invasive assessment of tissue stiffness, which is critical for early detection and monitoring of diseases such as liver fibrosis, breast cancer, and thyroid nodules.

Shear wave elastography (SWE) has emerged as a leading modality, leveraging acoustic radiation force to generate shear waves and measure their propagation speed through tissue. This quantitative approach provides reproducible stiffness measurements, reducing operator dependency compared to traditional strain elastography. Major manufacturers such as GE HealthCare, Siemens Healthineers, and Canon Medical Systems have integrated advanced SWE capabilities into their flagship ultrasound platforms. For instance, GE HealthCare’s LOGIQ series and Siemens Healthineers’ ACUSON systems now offer real-time, multi-parametric elastography, supporting both 2D and 3D imaging for comprehensive tissue characterization.

Strain elastography, which estimates tissue deformation in response to manual or physiological compression, continues to evolve with improved algorithms and user interfaces. Companies like Hitachi and Philips have refined their strain imaging technologies to enhance sensitivity and reduce artifacts, making them more accessible for routine clinical use. These advancements are particularly valuable in breast and thyroid imaging, where subtle differences in tissue elasticity can inform diagnostic decisions.

Beyond conventional shear wave and strain techniques, the industry is witnessing the emergence of hybrid and AI-enhanced elastography solutions. Artificial intelligence is being harnessed to automate region-of-interest selection, improve image quality, and provide decision support, as seen in recent product updates from Samsung Medison and Mindray. Additionally, research collaborations are exploring the integration of elastography with contrast-enhanced ultrasound and multiparametric imaging, aiming to deliver even more comprehensive diagnostic information.

Looking ahead, the next few years are expected to bring further miniaturization of elastography devices, increased portability, and expanded point-of-care applications. The convergence of advanced hardware, AI-driven analytics, and cloud connectivity is poised to make elastography more accessible in diverse clinical settings, from tertiary hospitals to community clinics. As regulatory approvals for new indications continue to expand, ultrasound elastography devices are set to play an increasingly central role in precision medicine and early disease detection worldwide.

Competitive Landscape: Leading Manufacturers and New Entrants

The competitive landscape for ultrasound elastography devices in 2025 is characterized by a mix of established global manufacturers and innovative new entrants, each contributing to rapid technological advancements and market expansion. The sector is dominated by a handful of multinational corporations with extensive portfolios in diagnostic imaging, while a growing number of specialized firms and startups are introducing novel solutions, particularly in software integration and portable device formats.

Among the leading manufacturers, GE HealthCare remains a key player, leveraging its global distribution network and robust R&D capabilities. The company’s LOGIQ and Vivid series integrate advanced elastography modules, supporting both shear wave and strain imaging for a range of clinical applications. Siemens Healthineers continues to innovate with its ACUSON ultrasound systems, which feature real-time elastography and AI-driven workflow enhancements, targeting liver, breast, and musculoskeletal diagnostics.

Philips is another major competitor, offering elastography as part of its EPIQ and Affiniti ultrasound platforms. The company emphasizes user-friendly interfaces and interoperability with hospital IT systems, aiming to streamline clinical workflows. Canon Medical Systems has also strengthened its position, particularly in Asia and Europe, with its Aplio series, which incorporates both 2D and 3D shear wave elastography for comprehensive tissue characterization.

In addition to these established firms, Samsung Medison is expanding its global footprint, focusing on affordability and accessibility with its RS series, which includes advanced elastography features. Mindray, a prominent Chinese manufacturer, is gaining traction in emerging markets with its Resona and DC series, offering competitive pricing and scalable elastography solutions.

The competitive landscape is further energized by new entrants and niche players. Companies such as SuperSonic Imagine (now part of Hologic) have pioneered real-time shear wave elastography, setting benchmarks for speed and quantitative accuracy. Startups and smaller firms are increasingly focusing on portable and point-of-care elastography devices, leveraging advances in miniaturization and cloud-based analytics.

Looking ahead, the next few years are expected to see intensified competition as manufacturers invest in AI integration, cloud connectivity, and expanded clinical indications. Strategic partnerships, mergers, and acquisitions are likely, as established players seek to incorporate disruptive innovations and broaden their product portfolios. The ongoing shift toward value-based healthcare and early disease detection will continue to drive demand for versatile, user-friendly elastography solutions worldwide.

Clinical Applications: Oncology, Hepatology, and Musculoskeletal Uses

Ultrasound elastography devices have become increasingly integral to clinical practice, particularly in the fields of oncology, hepatology, and musculoskeletal medicine. As of 2025, these devices are being rapidly adopted due to their non-invasive nature, real-time imaging capabilities, and ability to provide quantitative assessment of tissue stiffness—a key biomarker in various diseases.

In oncology, elastography is now routinely used to characterize tumors and guide biopsies. Devices from leading manufacturers such as GE HealthCare, Philips, and Siemens Healthineers offer advanced shear wave and strain elastography modules integrated into their ultrasound platforms. These technologies help differentiate benign from malignant lesions in organs such as the breast, thyroid, and prostate, improving diagnostic accuracy and reducing unnecessary invasive procedures. For example, breast elastography is now recommended in many clinical guidelines as an adjunct to conventional ultrasound for lesion characterization.

Hepatology remains one of the most established domains for elastography. Devices such as the FibroScan, developed by Echosens, have set the standard for non-invasive liver fibrosis assessment. In 2025, the use of point shear wave and 2D shear wave elastography is expanding, with major ultrasound system providers integrating these features to assess liver stiffness and steatosis in patients with chronic liver diseases, including hepatitis and non-alcoholic fatty liver disease (NAFLD). The ability to monitor disease progression and response to therapy without repeated biopsies is transforming patient management and is now embedded in hepatology care pathways worldwide.

Musculoskeletal applications are also gaining momentum. Elastography is increasingly used to evaluate tendons, muscles, and ligaments for injuries, inflammation, and degenerative changes. Companies like Canon Medical Systems and Mindray have introduced dedicated musculoskeletal elastography protocols, enabling clinicians to assess tissue elasticity and guide rehabilitation strategies. This is particularly valuable in sports medicine and orthopedics, where real-time feedback on tissue healing can inform return-to-play decisions.

Looking ahead, the next few years are expected to bring further integration of artificial intelligence and machine learning into elastography devices, enhancing image interpretation and workflow efficiency. The continued expansion of clinical indications, combined with growing evidence and guideline endorsements, suggests that ultrasound elastography will become a standard tool across multiple specialties by the late 2020s.

Regulatory Landscape and Standards (FDA, CE, and Global Bodies)

The regulatory landscape for ultrasound elastography devices in 2025 is characterized by evolving standards and increasing harmonization among major global authorities. These devices, which assess tissue stiffness for applications such as liver fibrosis staging and oncology, are classified as medical devices and thus subject to rigorous oversight.

In the United States, the U.S. Food and Drug Administration (FDA) continues to regulate ultrasound elastography systems under the 510(k) premarket notification pathway, typically as Class II devices. The FDA requires manufacturers to demonstrate substantial equivalence to predicate devices, with a focus on safety, effectiveness, and performance. In recent years, the FDA has issued updated guidance on the technical standards for ultrasound imaging, including elastography, emphasizing requirements for clinical validation, device labeling, and cybersecurity. Notably, leading manufacturers such as GE HealthCare, Siemens Healthineers, and Philips have all received FDA clearances for their elastography-enabled ultrasound platforms, reflecting ongoing innovation and compliance with regulatory expectations.

In Europe, the regulatory environment has shifted significantly with the full implementation of the Medical Device Regulation (MDR, Regulation (EU) 2017/745). As of 2025, all ultrasound elastography devices marketed in the European Economic Area must bear the CE mark under MDR, which imposes stricter requirements for clinical evidence, post-market surveillance, and traceability compared to the previous Medical Device Directive (MDD). Notified Bodies, such as TÜV SÜD and BSI, play a central role in conformity assessment. Major European and global manufacturers, including Echosens (noted for its FibroScan technology), have adapted their quality management systems and technical documentation to meet MDR standards, ensuring continued market access.

Globally, regulatory convergence is advancing through the work of organizations like the International Medical Device Regulators Forum (IMDRF), which promotes harmonized approaches to device classification, clinical evaluation, and post-market monitoring. In Asia, countries such as Japan and China have updated their regulatory frameworks to align more closely with international standards, with the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan and the National Medical Products Administration (NMPA) in China both requiring robust clinical data for elastography devices.

Looking ahead, the regulatory outlook for ultrasound elastography devices is expected to focus on real-world evidence, interoperability, and artificial intelligence integration. Authorities are likely to issue further guidance on software-driven features and data security, reflecting the increasing sophistication of these devices. Manufacturers will need to maintain agile compliance strategies to navigate this dynamic environment and ensure timely market access worldwide.

Regional Analysis: North America, Europe, Asia-Pacific, and Emerging Markets

The global market for ultrasound elastography devices is experiencing dynamic regional trends, with North America, Europe, Asia-Pacific, and emerging markets each contributing distinctively to sector growth and innovation in 2025 and the coming years.

North America remains a leading region, driven by high adoption rates of advanced diagnostic imaging, robust healthcare infrastructure, and ongoing product innovation. Major manufacturers such as GE HealthCare and Siemens Healthineers maintain significant market presence, offering a range of elastography-enabled ultrasound systems. The United States, in particular, benefits from favorable reimbursement policies and a strong focus on early disease detection, especially in oncology and hepatology. The region is also witnessing increased clinical research collaborations and FDA clearances for new elastography applications, further supporting market expansion.

Europe continues to demonstrate steady growth, underpinned by rising awareness of non-invasive diagnostic techniques and supportive regulatory frameworks. Countries such as Germany, France, and the United Kingdom are at the forefront, with hospitals and imaging centers integrating elastography into routine practice. European manufacturers like Esaote and Hitachi (with a strong European presence) are actively launching new systems tailored to local clinical needs. The European Union’s emphasis on cancer screening and chronic liver disease management is expected to drive further adoption through 2025 and beyond.

Asia-Pacific is emerging as the fastest-growing region, propelled by expanding healthcare access, government investments, and a rising burden of chronic diseases. Countries such as China, Japan, South Korea, and India are witnessing rapid deployment of elastography devices in both urban and rural settings. Local and multinational companies, including Canon Medical Systems and Samsung Medison, are investing in product localization and training initiatives to address diverse clinical requirements. The region’s large patient population and increasing focus on early diagnosis are expected to sustain double-digit growth rates in the near term.

Emerging markets in Latin America, the Middle East, and Africa are gradually adopting ultrasound elastography, supported by international partnerships and technology transfer initiatives. While market penetration remains lower compared to developed regions, efforts by global leaders such as Philips to expand distribution networks and provide affordable solutions are expected to accelerate uptake. These regions are also benefiting from mobile and portable elastography systems, which are well-suited to resource-limited settings.

Overall, regional dynamics in 2025 reflect a combination of technological innovation, healthcare policy evolution, and targeted investments, positioning ultrasound elastography devices for continued global expansion in the coming years.

Challenges and Barriers: Reimbursement, Training, and Adoption

The adoption of ultrasound elastography devices in clinical practice faces several notable challenges and barriers, particularly in the areas of reimbursement, clinician training, and broader market adoption. As of 2025, these factors continue to shape the pace and extent of integration of elastography technologies into routine diagnostic workflows.

Reimbursement Hurdles
One of the most significant barriers remains the variability and, in some regions, the absence of dedicated reimbursement codes for elastography procedures. While some countries and private insurers have begun to recognize the value of elastography—especially for liver fibrosis assessment—coverage is inconsistent. In the United States, the Centers for Medicare & Medicaid Services (CMS) have established CPT codes for certain elastography applications, but reimbursement rates can be modest and are not universally applied to all anatomical sites or clinical indications. This uncertainty can deter healthcare providers from investing in new elastography-capable systems, particularly in smaller practices or resource-limited settings.

Training and Operator Dependence
Ultrasound elastography, whether shear wave or strain-based, requires specialized training for accurate image acquisition and interpretation. The technique is operator-dependent, and proficiency varies widely among clinicians. Leading manufacturers such as GE HealthCare, Philips, Siemens Healthineers, and Canon Medical Systems have responded by offering dedicated training programs and on-site support. However, the learning curve remains a barrier, especially in regions where access to advanced training is limited. The need for standardized protocols and certification is increasingly recognized by professional societies, but widespread implementation is still in progress.

Adoption and Integration Challenges
Despite growing clinical evidence supporting elastography’s utility in liver, breast, thyroid, and musculoskeletal imaging, adoption rates vary. Larger academic centers and tertiary hospitals are more likely to invest in elastography-enabled systems, while smaller clinics may delay adoption due to cost concerns and uncertainty about return on investment. Device manufacturers are addressing this by integrating elastography into multipurpose ultrasound platforms, reducing incremental costs and simplifying workflow. Companies such as Echosens—a pioneer in transient elastography—continue to expand their product offerings and global reach, but market penetration in primary care and emerging markets remains limited.

Outlook
Looking ahead to the next few years, the sector is expected to benefit from ongoing efforts to standardize reimbursement, expand training initiatives, and demonstrate clinical and economic value. As more clinical guidelines incorporate elastography and as manufacturers streamline device usability, broader adoption is anticipated. However, overcoming the current barriers will require coordinated action among device makers, healthcare providers, and payers to ensure that the benefits of ultrasound elastography are accessible to a wider patient population.

Future Outlook: AI Integration, Portability, and Next-Gen Devices

The future of ultrasound elastography devices is being shaped by rapid advances in artificial intelligence (AI), miniaturization, and next-generation imaging technologies. As of 2025, leading manufacturers are actively integrating AI-driven features to enhance diagnostic accuracy, automate image interpretation, and streamline clinical workflows. For example, GE HealthCare and Siemens Healthineers have both announced AI-powered elastography solutions that assist clinicians in real-time tissue characterization, reducing operator dependency and inter-observer variability. These AI algorithms are increasingly capable of quantifying tissue stiffness, detecting subtle pathological changes, and providing decision support for liver fibrosis, breast lesions, and thyroid nodules.

Portability is another key trend, with compact and handheld elastography devices gaining traction in point-of-care settings. Companies such as Philips and Canon Medical Systems are developing lightweight, battery-operated systems that deliver high-quality elastography imaging outside traditional hospital environments. These portable devices are expected to expand access to advanced diagnostics in primary care, rural clinics, and resource-limited regions, supporting earlier disease detection and monitoring.

Next-generation elastography platforms are also focusing on multimodal imaging, combining shear wave, strain, and contrast-enhanced techniques for comprehensive tissue assessment. Samsung Medison and Hitachi are investing in systems that integrate multiple elastography modes, offering clinicians a broader diagnostic toolkit. Additionally, the use of advanced transducer materials and signal processing is improving spatial resolution and penetration depth, enabling more accurate evaluation of deep-seated organs.

Looking ahead, the convergence of AI, cloud connectivity, and telemedicine is poised to further transform the elastography landscape. Remote image analysis, automated reporting, and integration with electronic health records are expected to become standard features, facilitating collaborative care and longitudinal patient monitoring. Regulatory approvals for AI-assisted elastography applications are anticipated to accelerate, driven by growing clinical evidence and demand for precision medicine.

By the late 2020s, ultrasound elastography devices are likely to be more intelligent, portable, and versatile, supporting a wider range of clinical applications from oncology to musculoskeletal and cardiovascular imaging. The ongoing innovation by industry leaders and new entrants alike signals a dynamic outlook, with the potential to significantly improve patient outcomes and healthcare efficiency worldwide.

Company Spotlights: Canon Medical, Siemens Healthineers, GE Healthcare, and Mindray (sources: global.medical.canon, siemens-healthineers.com, gehealthcare.com, mindray.com)

In 2025, the ultrasound elastography device market is shaped by the innovation and global reach of leading manufacturers, notably Canon Medical, Siemens Healthineers, GE Healthcare, and Mindray. These companies are at the forefront of integrating elastography into clinical ultrasound systems, driving adoption in hepatology, oncology, and musculoskeletal imaging.

Canon Medical continues to expand its Aplio series, which features advanced shear wave and strain elastography. The company emphasizes real-time quantitative assessment, supporting liver fibrosis staging and tumor characterization. Canon’s focus on AI-powered workflow and image optimization is expected to further enhance diagnostic confidence and efficiency in 2025, as the company leverages its global R&D and service network to support clinical partners worldwide.

Siemens Healthineers remains a leader in ultrasound elastography, with its ACUSON Sequoia and ACUSON Juniper platforms offering both point shear wave and strain elastography. Siemens’ systems are recognized for their high sensitivity and reproducibility, particularly in liver and breast applications. In 2025, Siemens is expected to deepen integration of elastography into multi-modality workflows, supporting comprehensive patient management and remote collaboration through its digital health ecosystem.

GE Healthcare has made significant strides with its LOGIQ and Versana ultrasound families, which incorporate both 2D and 3D elastography capabilities. GE’s focus on accessibility and scalability is evident in its efforts to bring elastography to a broader range of care settings, including primary care and emerging markets. The company’s ongoing investment in AI and cloud connectivity is anticipated to streamline reporting and enable population health initiatives in the coming years.

Mindray, a major global supplier, has rapidly advanced its elastography offerings, integrating both shear wave and strain elastography into its Resona and DC series. Mindray’s systems are known for user-friendly interfaces and affordability, making elastography more accessible in diverse healthcare environments. In 2025, Mindray is expected to expand its international presence, with a focus on training and support to drive adoption in both developed and emerging markets.

Looking ahead, these four companies are poised to shape the future of ultrasound elastography through continued innovation, AI integration, and global outreach. Their efforts are likely to accelerate the clinical adoption of elastography, improve diagnostic accuracy, and expand access to advanced imaging technologies worldwide.

Sources & References

Electrophysiology Market Outlook 2025–2033 | Growth Trends, Innovations & Investment Insights

Watch this video on YouTube.

Ultrasound Elastography Devices 2025: Rapid Growth & Breakthrough Innovations Ahead

ByQuinn Parker